Predictive and prognostic value of FDG-PET

por de Geus-Oei, Lioe-Fee, Oyen, Wim J.G.
Publicado 2008

Nuclear medicine imaging and therapy of neuroendocrine tumours

por Gotthardt, Martin, Dijkgraaf, Ingrid, Boerman, Otto C, Oyen, Wim J G
Publicado 2006

Radiolabelled peptides for oncological diagnosis

por Laverman, Peter, Sosabowski, Jane K., Boerman, Otto C., Oyen, Wim J. G.
Publicado 2012

(68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET

por Brom, Maarten, Oyen, Wim J. G., Joosten, Lieke, Gotthardt, Martin, Boerman, Otto C.
Publicado 2010

FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment

por Quak, Elske, Kovacs, Iringo, Oyen, Wim J. G., van der Graaf, Winette T. A.
Publicado 2015

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation

por van der Zande, Kim, Oyen, Wim J. G., Zwart, Wilbert, Bergman, Andries M.
Publicado 2021

Methodological considerations in quantification of oncological FDG PET studies

por Vriens, Dennis, Visser, Eric P., de Geus-Oei, Lioe-Fee, Oyen, Wim J. G.
Publicado 2009

Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations

por van Dalen, Jorn A., Vogel, Wouter V., Corstens, Frans H.M., Oyen, Wim J.G.
Publicado 2007

Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study

por Schinagl, Dominic A. X., Span, Paul N., Oyen, Wim J., Kaanders, Johannes H. A. M.
Publicado 2011

Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma

por Gilles, Rozemarie, de Geus-Oei, Lioe-Fee, Mulders, Peter F. A., Oyen, Wim J. G.
Publicado 2011

The revision of the pharmaceutical legislation — it is time to act for nuclear medicine in Europe

por Patt, Marianne, Decristoforo, Clemens, de Martini, Amélie, Koole, Michel, Oyen, Wim J. G., Kiss, Oliver C.
Publicado 2023

Radiolabeled antibodies in renal cell carcinoma

por Stillebroer, Alexander B., Oosterwijk, Egbert, Oyen, Wim J.G., Mulders, Peter F.A., Boerman, Otto C.
Publicado 2007

Antibody therapy in renal cell carcinoma

por Oosterwijk, Egbert, Boerman, Otto C., Oyen, Wim J. C., Old, Lloyd J., Mulders, Peter F. A.
Publicado 2008

Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides

por Vegt, Erik, Eek, Annemarie, Oyen, Wim J. G., de Jong, Marion, Gotthardt, Martin, Boerman, Otto C.
Publicado 2009

Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy

por Bashir, Usman, Tree, Alison, Mayer, Erik, Levine, Daniel, Parker, Chris, Dearnaley, David, Oyen, Wim J. G.
Publicado 2019

Colorectal cancer: the role of PET/CT in recurrence: Wednesday 5 October 2005, 14:00–16:00

por Vogel, Wouter V, Wiering, Bastiaan, Corstens, Frans H M, Ruers, Theo J M, Oyen, Wim J G
Publicado 2005

F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection

por Simons, Koen S., Pickkers, Peter, Bleeker-Rovers, Chantal P., Oyen, Wim J. G., van der Hoeven, Johannes G.
Publicado 2009

FDG-PET/CT based response-adapted treatment

por de Geus-Oei, Lioe-Fee, Vriens, Dennis, Arens, Anne I.J., Hutchings, Martin, Oyen, Wim J.G.
Publicado 2012

Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry

por van de Watering, Floor C. J., Rijpkema, Mark, Robillard, Marc, Oyen, Wim J. G., Boerman, Otto C.
Publicado 2014

Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma

por Lütje, Susanne, de Rooy, Jacky W. J., Croockewit, Sandra, Koedam, Emmeline, Oyen, Wim J. G., Raymakers, Reinier A.
Publicado 2009